Results 41 to 50 of about 29,874,260 (303)
IGF-I signalling in bone growth: Inhibitory actions of dexamethasone and IL-1 beta [PDF]
, 2007 To determine if glucocorticoids and proinflammatory cytokines inhibit bone growth through a common mechanism involving impaired IGF-I ...
Macrae, V.E. +7 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source
IGF-1-induced hypertrophic changes in cardiomyocyte morphology are mediated by PC1.
, 2021 Cardiomyocytes were transfected with scrambled (Scr) or PC1 siRNA (siPC1), incubated for 24 h, and then treated with IGF-1 (10 nM) or vehicle for 24 h.
César Vásquez-Trincado (11292276) +10 more
core +1 more source
Molecular Oncology, EarlyView.The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka +9 more
wiley +1 more source
Chronic inflammation and the growth hormone/insulin-like growth factor-1 axis
Central European Journal of Immunology, 2021 Interactions between growth hormone (GH), insulin-like growth factor-1 (IGF-1), and the immune system are complex, bidirectional, but not fully explained.
Ewelina Witkowska-Sędek, Beata Pyrżak
doaj +1 more source
Studies on Insulin/IGF‐1 Hybrid and IGF‐1 Growth‐Promoting Functional Region [PDF]
IUBMB Life, 2000 AbstractSingle‐chain insulin/IGF‐1 hybrid‐[Ins/IGF‐1(C)], single‐chain porcine insulin precursor‐(PIP), and B10Asp PIP were prepared by protein engineering. Their growth‐promoting activities in mouse breast cancer cell line GR2H6 are 10, 0.2, and 2 times that of insulin, respectively, and 29%, 0.6%, and 6% of that of IGF‐1, indicating that the C domain
P, Wang, R R, Cai, Y M, Feng, Y S, Zhang
openaire +2 more sources
Molecular Oncology, EarlyView.The proposed mechanism of action for the CDK12/13 inhibitor and cyclin K degrader, CT7439. CDK12/13 inhibition interrupts transcription elongation, leading to increased DNA damage that results in cell death. This agent is a potentially novel treatment option for patients with colorectal cancer. Created in BioRender. Cyclin‐dependent kinase (CDK) 12 and
Wylie K. Watlington +10 more
wiley +1 more source
Haematologica, 2010 Background Alterations in the PI3K/Akt pathway are found in a wide range of cancers and the development of PI3K inhibitors represents a promising approach to cancer therapy.
Nicolas Chapuis +12 more
doaj +1 more source
Nuclear targeting of IGF-1 receptor in orbital fibroblasts from Graves' disease: apparent role of ADAM17. [PDF]
PLoS ONE, 2012 Insulin-like growth factor-1 receptor (IGF-1R) comprises two subunits, including a ligand binding domain on extra- cellular IGF-1Rα and a tyrosine phosphorylation site located on IGF-1Rβ.
Neil Hoa +6 more
doaj +1 more source